A detailed history of Diadema Partners LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Diadema Partners LP holds 76,220 shares of URGN stock, worth $1.08 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
76,220
Previous 50,000 52.44%
Holding current value
$1.08 Million
Previous $533 Million 58.31%
% of portfolio
0.22%
Previous 0.23%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$9.27 - $12.13 $243,059 - $318,048
26,220 Added 52.44%
76,220 $843 Million
Q4 2024

Feb 14, 2025

BUY
$10.52 - $13.11 $526,000 - $655,500
50,000 New
50,000 $533 Million

Others Institutions Holding URGN

About UroGen Pharma Ltd.


  • Ticker URGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,740,500
  • Market Cap $322M
  • Description
  • UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...
More about URGN
Track This Portfolio

Track Diadema Partners LP Portfolio

Follow Diadema Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diadema Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Diadema Partners LP with notifications on news.